Hefei Anderson Pharmacy

Hefei Anderson Pharmaceutical is a Chinese biopharmaceutical company focused on the research, development, and commercialization of novel anti-tumor therapeutics and cell-based therapies. The company's lead candidate is Taxipeptide (紫杉肽), a first-in-class peptide-drug conjugate that links paclitaxel with a peptide carrier to improve water solubility and tumor targeting while reducing side effects like hair loss and toxicity. Taxipeptide has completed Phase II clinical trials and was recognized as a key national drug development project in China. Additionally, Hefei Anderson collaborates on dendritic cell (DC) therapy technologies and other oncology programs to address unmet medical needs in cancer treatment.